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Abstract
Background: The aim of this trial was to assess the rel-
ative efficacy of a sage/echinacea spray and a chlor-
hexidine/lidocaine spray in the treatment of acute
sore throats.
Methods: This was a multicenter, randomized, double-
blind, double-dummy controlled trial carried out in
eleven general practices in Switzerland. A total of 154
patients (133 analyzed in per protocol collective) at
least 12 years old with acute sore throat present for
not more than 72 hours prior to inclusion and with a
throat score ≥6 participated in the study. They used ei-
ther an echinacea/sage spray or a chlorhexidine/ lido-
caine spray with two puffs every 2 hours, in a double-
dummy blinded manner, up to 10 times daily until they
were symptom-free, for a maximum of 5 days. The
main outcome measures was the comparison of re-
sponse rates during the first three days. A response
was defined as a decrease of at least 50% of the total
symptoms compared to baseline.
Results: The echinacea/sage treatment exhibited simi-
lar efficacy to the chlorhexidine/lidocaine treatment in
reducing sore throat symptoms during the first 3 days
(P(x<Y) = .5083). Response rates after 3 days were
63.8% in the echinacea/sage group and 57.8% in the
chlorhexidine/lidocaine group. For all secondary para-
meters, such as time to becoming symptom free,
throat pain, and global assessments of efficacy by the
physician and patient, no difference between the two
treatments was seen. They were both very well tolerat-
ed.
Conclusion: An echinacea/sage preparation is as effica-
cious and well tolerated as a chlorhexidine/lidocaine
spray in the treatment of acute sore throats.
Key words: Clinical trial – sore throat – echinacea –
salvia – chlorhexidine - lidocaine
INTRODUCTION
Acute sore throats are one of the most commonly
seen conditions in general practice, rating as the third
most common disease to be treated in the United
States [1]. The disease encompasses any upper respira-
tory tract infection most often caused by viruses or
bacteria in which pain in the throat is the predominant
symptom [2], mostly accompanied by inflammation
and swelling of the pharyngeal region. The total costs
for treatment and missed work are estimated in the
United States to be $1.3 billion annually. Only about
10–20% of patients with a sore throat are streptococ-
cus positive in the throat. Most patients have viral in-
fections and benefit from symptomatic treatment
alone [3]. Pain relief is one of the main reasons a pa-
tient with a sore throat sees a doctor, and NSAIDs
such as paracetamol, ibuprofen [4], diclofenac, and
acetylsalicylic acid [5] are taken, or anesthetic sub-
stances such as lidocaine are used. Additionally, sub-
stances such as chlorhexidine, with a broad antimicro-
bial activity, are in use [6]. Further treatment options
are herbal medicinal products that patients often use
to ease symptoms.
The purple coneflower, Echinacea purpurea, is a
medicinal plant with a long tradition of being used as
a remedy in the treatment of upper respiratory tract
infections, and a recent review confirmed the efficacy
of echinacea preparations in the treatment and pro-
phylaxis of these infections [7]. The plant has anti-in-
flammatory and immune modulatory properties that
seem to be mediated by endocannabinoid receptor
CB2-induced upregulation of TNF-α mRNA[8]; in
addition, antiviral and antibacterial properties have
been reported [9].
Another medicinal plant that has been used tradi-
tionally and is also recommended for use in infections
and inflammations of the mouth is the common sage,
Salvia officinalis. Sage compounds have anti-inflam-
matory, antibacterial, antinociceptive, and astringent
properties [10]. Because both plants are traditionally
used in the treatment of upper respiratory tract infec-
tions and for sore throats, we wanted to see if an
herbal treatment could exhibit an efficacy similar to
that of synthetic compounds. In this trial, we com-
pared the efficacy of an echinacea/sage throat spray
to that of a chlorhexidine/lidocaine spray in the treat-
ment of acute sore throats.
PARTICIPANTS, METHODS AND STATISTICS
PARTICIPANTS
Patients were recruited among 11 general practices in
Switzerland from February to August 2006. The study
was approved by the relevant ethical committees and
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out according to the guidelines of Good Clinical Prac-
tice and the ethical obligations of the Declaration of
Helsinki.
Inclusion criteria were age >12 years; acute pharyn-
gitis or tonsillitis with symptoms of throat pain and
inflammation of the pharynx and/or tonsils; onset of
sore throat less than 72 hours before inclusion into the
study; a Tonsillopharyngitis Severity Score ≥6; and
written informed consent.
Exclusion criteria included the use of the following
within the respective time frames preceding the start
of the study: analgesics <12 hours; antibiotics <24
hours; topical throat pain medication <4 hours; or sys-
temic corticosteroids within the last month. Other ex-
clusion criteria were symptoms of primary bacterial
pharyngitis or secondary bacterial infection; serious ill-
ness such as tumors; allergy to one of the ingredients;
pregnancy or lactation; hypersensitivity to ibuprofen;
or participation in another clinical trial in the previous
30 days.
TREATMENT AND BLINDING
Patients received either a 50-ml bottle of an echi-
nacea/sage spray containing an aqueous alcoholic
(57.3% m/m ethanol) fresh-plant extract of E. pur-
purea (95% aerial parts and 5% root) and of leaves of
S. officinalis (863.3 mg/ml E. purpurea flowering aeri-
al parts tincture, Drug Extract Ratio 1:12; 45.5 mg/ml
E. purpurea root tincture DER 1:11; and 430.0
mg/ml S. officinalis leaves tincture DER 1:17; batch
no. 019182) or a spray containing 1% chlorhexidine
gluconate and 2% lidocaine hydrochloride (Colluno-
solﾮ, Sanofi AG). The echinacea tinctures (Echina-
forceﾮ) were used as a concentrate, but the sage tinc-
ture was used without previous evaporation to main-
tain the valuable sage essential oils.
Placebos were produced with inert flavoring sub-
stances from G￼nther Aromen GmbH, Beinwil a. S.,
Switzerland. Because this was a double-dummy blind-
ed study, each patient also received with the verum a
placebo corresponding to the other spray treatment
that was similar in appearance, taste, and smell. The
verum and the placebo bottles were issued in a sealed
box, together with a package of 20 tablets of ibupro-
fen 200 mg that served as rescue medication if pain
symptoms were too severe.
To check blinding at the end of the treatment, pa-
tients were asked to guess which bottle contained the
treatment.
Compliance was checked with weighing of the re-
turned bottles and the count of used rescue medica-
tion, and patients documented in a diary how many
times they had applied each spray daily.
Patients had to apply spray every 2 hours with two
puffs to the pharyngeal area up to a maximum of 10
times daily. Treatment duration was until illness was
resolved or for a maximum of 5 consecutive days.
PRIMARY PARAMETER
Patients filled out a diary three times daily (morning,
midday, evening), recording the Tonsillopharyngitis
Severity Score [11], which consists of the symptoms
of throat pain, difficulty in swallowing, salivation, ery-
thema, and fever (rated on a 4-point scale: 0 = none, 1
= mild, 2 = moderate, 3 = severe).
The primary parameter was defined as the compari-
son of the response rates of the two treatment groups
after the first, second, and third days. A response to
treatment is defined as a reduction by 50% of the total
baseline score taken prior to treatment start.
SECONDARY PARAMETER
The secondary parameters for assessing efficacy were
a comparison of response rates after the fourth and
fifth days of treatment; reduction of the total symp-
tom score (throat pain, difficulty swallowing, saliva-
tion, erythema, and fever symptoms) after days 1 to 5
compared to the baseline score; time taken to become
symptom free (total score ≤2) within the 5-day
treatment period; percentage of patients with a reso-
lution of illness by day 5 (objective assessment by
physician, total score ≤2); Visual Analogue Scale VAS
for throat pain; number of ibuprofen tablets used;
and global assessment of efficacy by the physician
and patient.
Safety parameters considered were frequency of ad-
verse events, global assessment of tolerability by
physician and patient, vital parameters (pulse, blood
pressure, body temperature), and laboratory blood val-
ues [ALAT (GPT, ALT), ASAT (GOT, ALT), total
bilirubin, plasma glucose, serum creatinine, ESR (1 h),
CRP, total cholesterol, erythrocytes, MCHC, MCH,
MCV, hematocrit, hemoglobin, leukocytes, and throm-
bocytes].
SAMPLE SIZE, RANDOMIZATION, AND STATISTICAL
ANALYSIS
The Mann-Whitney statistic P(x<Y) was used as a
measure of relevance of group differences as being
the associated effect size measure for the Wilcoxon-
Mann-Whitney test. It is defined as the probability
that a randomly selected patient from the test group is
better off than a randomly selected patient from the
reference group. The maximum acceptable difference
(non-inferiority region) was predefined by means of
Mann-Whitney statistics as P(X<Y) = 0.36 (medium-
sized/relevant difference).
With a non-inferiority margin of P(X<Y) = 0.36
and a one-sided test of non-inferiority at a level of
significance of α = 0.025 and a power of 80%, 67
evaluable patients in each treatment group were need-
ed. With respect to dropouts and because the per pro-
tocol collective was the population analyzed for the
primary parameter, a total of 150 patients had to be
recruited.
Randomization codes were computer-generated in
blocks of four (RanCode, Version 3.6, IDV-Gauting,
Germany) with a randomization ratio of 1:1.
The null hypothesis stated that chlorhexidine/lido-
caine reaches at least a medium-sized superiority to the
sage/echinacea spray. The alternative hypothesis stated
that sage/echinacea is on at least one of the first three
days less than medium-sized inferior to chlorhexi-
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for non-inferiority was performed using a generalized
Wilcoxon-Mann-Whitney test (directional test) accord-
ing to Wei-Lachin[12] with α = 0.025, one-sided. If
the combined global test gave a significant result then
efficacy was proven in a confirmatory way (at least one
null hypothesis of a null difference cannot be true). If
the summarizing test gave a significant result, then the
three single efficacy criteria could be tested univariate-
ly in a top-down procedure with full alpha according
to the closed testing principle. The confirmatory tests
for non-inferiority were performed applying the “con-
fidence interval approach.”
The non-inferiority of echinacea/sage compared to
chlorhexidine/lidocaine could be accepted, if the low-
er bound of the one-sided 97.5% confidence interval
of the Mann-Whitney statistic was greater than 0.36,
corresponding to an overall two-sided level of signifi-
cance of α = 0.05. Confidence limits were calculated
using the validated test system TESTIMATE (Version
6.4).
Secondary parameters were analyzed in a descrip-
tive manner with 95% confidence intervals.
RESULTS
PATIENT CHARACTERISTICS AND FLOW THROUGH THE
STUDY
A total of 154 patients were screened, randomized,
and treated, and they formed the safety population.
There were 80 patients allocated to the echinacea/sage
group and 74 to the chlorhexidine/lidocaine group.
Two patients in the echinacea/sage and one in
chlorhexidine/lidocaine were lost to follow-up, and in
each group nine patients were excluded from the per
protocol population mainly because of incorrect use
of the study medication; this population finally con-
sisted of 133 patients (Fig. 1).
The baseline characteristics between treatment
groups were comparable, with only a significant
difference found for age (P<0.05), with the chlor-
hexidine/lidocaine group having younger patients
(Table 1). The throat score was somewhat higher
in the chlorhexidine/lidocaine group. The average
study duration was 5.6 days in the echinacea/
sage and 6.4 days in the chlorhexidine/lidocaine
group.
COMPLIANCE AND BLINDING
The patients in the per protocol population in the
echinacea/sage group used an average 11.7 ﾱ 6.4 g of
the verum spray and 7.8 ﾱ 5.4 g of the placebo spray;
the chlorhexidine/lidocaine group used 10.1 ﾱ 6.9 g of
the verum and 14.2 ﾱ 10.5 g of the placebo spray.
Even though more of the spray was consumed in the
chlorhexidine/lidocaine group, this difference was not
statistically significant (P = .109).
The blinding question showed that in the echi-
nacea/sage group, 78.3% of the patients guessed the
verum correctly and 75.4% of the patients guessed the
placebo correctly. In the chlorhexidine/lidocaine
group, only 26.6% guessed the verum correctly and
70.3% thought their echinacea/sage placebo was actu-
ally the verum.
EUROPEAN JOURNAL OF MEDICAL RESEARCH 408 September 1, 2009
Fig. 1. Flow chart of participants in the trial.
4. Suter:Umbruchvorlage  17.08.2009  17:40 Uhr  Seite 408EFFICACY
All efficacy data are shown for the per protocol popu-
lation because it is needed for confirmatory analysis.
Figure 2 shows the results for the primary parameter,
the response rates in both treatment groups during the
first 3 days. The echinacea/sage treatment was similar
in efficacy to the chlorhexidine/lidocaine treatment
for the 3 days together (P(x<Y) = .5083) and for each
single day of the first 3 days. The results for the
Mann-Whitney-Statistics are given in Table 2.
The response rates for day 4 were 69.6% for echi-
nacea/sage and 70.3% for chlorhexidine/lidocaine (P
= .5374); respectively for day 5, they were 73.9% and
79.7% (P = .7857).
Figure 3 illustrates the reduction in symptoms dur-
ing the time course of the 5 days; there was no statisti-
cal difference between the two groups through the
time period.
The time point at which 50% of patients in the
echinacea/sage group were symptom free (total score
≤2) was the evening of day 4, while 50% of patients
in the chlorhexidine/lidocaine group achieved symp-
tom-free status the morning of day 5 (P = .6741).
At day 5, 50.7% of the patients of the echi-
nacea/sage and 56.3% of the chlorhexidine/lidocaine
group were assessed to be symptom-free.
The pain recorded on a 100-mm Visual Analogue
Scale decreased under echinacea/sage from 72.6 to 7.3
mm, and with chlorhexidine/lidocaine from 77.1 to
8.4 mm after 5 days of treatment (P = .6352).
In the echinacea/sage group, 25 patients took 6.2
ibuprofen tablets, and in the chlorhexidine/lidocaine
group, 30 patients consumed 7.0 ibuprofen tablets
during the observation period. A subanalysis with pa-
tients taking ibuprofen compared to those taking none
showed no differences between the two populations in
the efficacy parameters (data not shown).
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Table 1. Characteristics of patients in the two treatment groups for the per protocol population.
Echinacea/sage Chlorhexidine/lidocaine P value
Number of patients 69 64
Mean age in years (SD) 41.6 (18.7) 33.8 (13.1) 0.2081
Male 23 20 >0.8542
Total throat score at baseline (SD) 8.8 (1.5) 9.5 (1.5) 0.0041
Throat pain at baseline (100 mm VAS) (SD) 72.6 (17.9) 77.1 (19.9) 0.0491
Mean study duration (SD) 5.6 (2.1) days 6.4 (4.8) days 0.4941
Mean amount of verum used (SD) 11.7 (6.4) g 10.1 (6.9) g
Mean amount of placebo used (SD) 7.8 (5.4) g 14.2 (10.5) g
Blinding
Number of patients identifying verum correctly (%) 54 (78.3) 17 (26.6)
Number of patients identifying placebo correctly (%) 52 (75.4) 15 (23.4)
1Wilcoxon two-sample tests
2Fisher’s exact test
Table 2. Wilcoxon Test/Mann-Whitney statistic for day 1 to day 3 and combined hypothesis (per protocol collective).
Criterion Mann-Whitney Left-sided limit of P value nn
statistic the confidence interval (U-Test) echinacea/sage chlorhexidine/lidocaine
Day 1 0.4949 0.4367 0.5681 64 69
Day 2 0.5003 0.4174 0.4968 64 69
Day 3 0.5298 0.4469 0.2408 64 69
Global
(Day 1- Day 3) 0.5083 0.4482 0.3928
Fig. 2. Relative frequency of patients with reduction in the
sore throat score by at least 50% during the first 3 days of
treatment of the per protocol population (n = 133). The grey
bars represent the chlorhexidine/lidocaine (n = 64) and the
black bars the echinacea/sage treatment (n = 69). (P = .5083,
Mann-Whitney-Statistic).
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good in 88.4% of patients using the echinacea/sage
spray and in 89.1% of all patients using the chlorhexi-
dine/lidocaine spray. Patients’ efficacy ratings were
similar, with “very good” or “good” in 89.9% of the
echinacea/sage and 89.1% of the chlorhexidine/lido-
caine cases (Fig. 4).
Because less spray was used in the chlorhexi-
dine/lidocaine group, there was the possibility of an
influence on the outcome in favor of the echi-
nacea/sage spray; thus, we conducted a further analy-
sis of the symptom reduction during the first 3 days
with the amount of verum consumed in each group
taken as the covariate. In this analysis, on days 1 and 2,
a slight advantage of the echinacea/sage spray as in
the primary analysis can be seen; on day 3, the advan-
tage of chlorhexidine/lidocaine is more noticeable but
not statistically significant (P = .610; data not shown).
SAFETY
A total of six adverse events were observed among five
patients. These were one rash on the mucosa, one
burning sensation and dryness of the throat, and one
patient with joint pains in the echinacea/sage group
and one swelling of the tongue and a bitter taste in the
mouth with chlorhexidine/lidocaine. All events except
for the joint pains were seen to have a probable rela-
tionship to the study medication and were transient
and of mild or moderate intensity, except for the bitter
taste in the mouth reported by a patient in the chlor-
hexidine/lidocaine group, which was rated as severe.
The tolerability of the safety population was rated
as good or very good for the chlorhexidine/lidocaine
spray by 94.5% and for the echinacea/sage spray by
93.6% of the patients. The investigator ratings were
almost the same with very good and good for 93.2%
of all patients with chlorhexidine/lidocaine, and the
same ratings for 96.2% of all patients in the echi-
nacea/sage group. Vital parameters and laboratory val-
ues remained the same in both groups except for the
C-reactive protein, which decreased under echi-
nacea/sage treatment from 16.4 to 5.9 mg/l and under
chlorhexidine/lidocaine from 23.0 to 6.4 mg/l.
DISCUSSION
Even though the occurrence of pharyngitis is very
common and only 10–20% are streptococcal throat
positive and require antibiotic treatment [4], only a few
studies have been carried out on non-streptococcal
sore throats, and no guidelines for studies or validated
scores are available. We thus designed the trial based
on the best available information. Nevertheless, we
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Fig. 3. Reduction of the total symptom score (per pro-
tocol collective) during 5 days of treatment of the per
protocol population (n = 133). The grey triangles show
the chlorhexidine/lidocaine (n = 64) and the black cir-
cles the echinacea/sage treatment (n = 69).
Fig. 4. Assessment of efficacy at the end of the treatment by investigators and patients (per protocol population, n = 133). (A =
investigators, B = patients).
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criteria to be clinically relevant.
The choice of the reference treatment is always a
matter of discussion. We chose the chlorhexi-
dine/lidocaine spray in accordance with the relevant
ICH guideline[13] because it has been on the market
as a registered product in Switzerland since 1992 and
is one of the leading products for treatment of acute
sore throats in this country. Furthermore, the con-
stituents chlorhexidine and lidocaine have long been in
use and are well investigated. Chlorhexidine has been
used over the past 25 years for a broad range of appli-
cations such as skin and surgical hand disinfection and
for oral diseases and is used as gold standard among
anti-plaque treatments. Its effectiveness is attributed to
its bactericidal and bacteriostatic effects and its sub-
stantivity within the oral cavity.[6]
Lidocaine is a local anesthetic with a long history
used topically for a variety of indications[14] .Even
though chlorhexidine/lidocaine sprays are marketed in
several countries, there are no studies available on a
combination product in sore throats. Lidocaine has
been investigated in studies with sore throat or in the
oral mucosa. A study of 5% lidocaine ointment in
healthy volunteers showed a significant pain reduction
in the oral mucosa compared to placebo during 5 min-
utes of induced pain.[15] A recent trial from Wonne-
mann[16] found that the use of 8 mg lidocaine as
tablets in patients with sore throat decreased the acute
pain within the first 2 hours significantly compared to
placebo (P<.001), a decrease that held for a longer
treatment period of up to 48 hours after repeated in-
take of lidocaine tablets. The analgesic properties of
lidocaine in the treatment of sore throat are thus clini-
cally proven.
In our study, we showed that with the combination
of sage and echinacea, the sore throat symptoms were
reduced significantly. This finding is in line with clini-
cal studies for sage and echinacea that examined the
treatment of sore throats:
Hubbert et al. investigated the analgesic efficacy of
three different sage spray formulations against placebo
in patients with sore throats.[17] The pain during the
first 2 hours was significantly lower than with placebo
(P = .0021), and the pain measured over 3 days was
significantly lower than placebo (P<.0001). The treat-
ment was very well tolerated.
In four placebo-controlled clinical trials with an
echinacea preparation, sore throat was also assessed as
an efficacy parameter. All trials showed a benefit for
echinacea but it was not always statistically signifi-
cant[18-21]. These data indicate that with an echinacea
preparation alone, no significant pain reduction in sore
throats can be achieved, and as a consequence, a com-
bination with sage is useful. But because reviews have
confirmed the good prophylactic and acute efficacy of
echinacea in upper respiratory tract infections,[11]
echinacea also must contribute to the efficacy of the
investigated throat spray.
The frequent use of ibuprofen can lead to the as-
sumption that the study results are biased. This does
not appear to be the case, however; in both treatment
groups, about the same amount of ibuprofen was tak-
en and, surprisingly, a subanalysis showed that the
study results were the same whether patients took
ibuprofen or not. Another interesting finding was that
the majority of the patients in the chlorhexi-
dine/lidocaine group thought they were actually re-
ceiving the echinacea/sage treatment. The amount of
spray used shows that the patients also preferred the
echinacea/sage treatment. We assume that this was
mainly because of the taste of the echinacea/sage
verum and placebo, which was preferred to the slightly
sweetish taste of the chlorhexidine/lidocaine treat-
ment. However, this finding also shows that the study
was very well blinded, which is often hard to achieve
with non-encapsulated study medications.
There is discussion in the treatment of pharyngitis
of the extent to which antibiotics should be used. For
practitioners and primary care institutions, there are
simple and validated questionnaires available such as
the McIsaac Score,[22] to differentiate between pa-
tients needing antibiotics and those needing simple
analgesic treatment. Nevertheless, short-term use of
analgesics also can be problematic. A study investigat-
ing ibuprofen, paracetamol, or aspirin use for up to 7
days in the treatment of cold symptoms and sore
throats found an adverse event rate of 12% for
ibuprofen, 15.7% for aspirin, and 12.3% for paraceta-
mol.[23] In our study, we found for the echinacea/
sage treatment a low adverse event rate of 3.8%. This
is in line with other complementary medicinal prod-
ucts, which have proven to be well tolerated in the
treatment of pharyngitis.[24] Because complementary
medicines are generally well accepted and frequently
used among patients[25], it is necessary to offer pa-
tients well-investigated and safe products.
CONCLUSIONS
The echinacea/sage spray demonstrated equivalent ef-
ficacy compared to the chlorhexidine/lidocaine treat-
ment and was very well tolerated. It is a recommend-
able alternative to common NSAIDs or other synthet-
ic products in the treatment of acute sore throats.
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